News & Updates

The combination of ivosidenib and azacitidine (IVO-AZA) improves event-free and overall survival (OS) vs AZA alone in patients with acute myeloid leukaemia (AML) bearing somatic mutations in isocitrate dehydrogenase 1 (IDH1), the AGILE trial has shown.

The treatment scope of oral anticoagulants (OACs) remains poor despite increasing treatment rates among high-risk atrial fibrillation (AF) patients, which is primarily credited to the expanding direct oral anticoagulant (DOAC) use, reports an Israel study.

Adjuvant treatment with metformin does not improve outcomes in most patients with early breast cancer in a phase III study, suggesting that metformin should not be used as a breast cancer treatment in these patients.

Prophylactic use of the investigational antithrombin siRNA fitusiran significantly reduces bleeding events in people with severe haemophilia compared with on-demand treatment with clotting factor concentrates, according to the phase III ATLAS-A/B trial presented at ASH 2021.

Low vitamin D levels were associated with an increased incidence of pain events leading to hospital admission among children with sickle cell disease (SCD), according to a study presented at ASH 2021.